High infiltration of B cells in tertiary lymphoid structures, TCR oligoclonality, and neoantigens are part of esophageal squamous cell carcinoma microenvironment

Luciana Rodrigues Carvalho Barros,Paulo Thiago De Souza‐Santos,Marco Antonio Marques Pretti,Gustavo Fioravanti Vieira,Marcelo Alves De Souza Bragatte,Marcus Fabiano De Almeida Mendes,Martiela Vaz De Freitas,Nicole De Miranda Scherer,Ivanir Martins De Oliveira,Davy Carlos Mendes Rapozo,Priscila Valverde Fernandes,Tatiana De Almeida Simão,Sheila Coelho Soares‐Lima,Mariana Boroni,Luis Felipe Ribeiro Pinto,Martin Hernan Bonamino
DOI: https://doi.org/10.1002/JLB.5MA0720-710RRR
2020-08-24
Journal of Leukocyte Biology
Abstract:Esophageal squamous cell carcinoma (ESCA) exhibits high intratumoral molecular heterogeneity posing a challenge to cancer therapy. Immune checkpoint blockade therapy has been approved for this disease, but with modest results. RNA‐Seq data from paired tumor and surrounding nonmalignant tissue from 14 patients diagnosed with ESCA without previous treatment and from The Cancer Genome Atlas‐ESCA cohort were analyzed. Herein, we investigated ESCA immune landscape including mutation‐derived neoantigens and immune cell subpopulations. Tumor‐associated antigen expression was determined by in silico analyses and confirmed by immunohistochemistry showing that PRAME, CEACAM4, and MAGEA11 proteins are expressed on tumors. Immune checkpoint molecules gene expression was higher in the tumor compared with surrounding nonmalignant tissue, but its expression varies greatly among patients. TCR repertoire and BCR transcripts analysis evidenced low clonal diversity with one TCR clone predicted to be specific for a MAGEA11‐derived peptide. A high number of B‐cell clones infiltrating the tumors and the abundance of these cells in tertiary lymphoid structures observed in ESCA tumors support B cells as a potential immune modulator in this tumor.
immunology,cell biology,hematology
What problem does this paper attempt to address?